Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States

Abstract Background The anti-fibrotic medications nintedanib and pirfenidone were approved in the United States for use in patients with idiopathic pulmonary fibrosis several years ago. While there is a growing body of evidence surrounding their clinical effectiveness, these medications are quite ex...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Timothy M. Dempsey, Viengneesee Thao, James P. Moriarty, Bijan J. Borah, Andrew H. Limper
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2022-01-01
סדרה:	BMC Pulmonary Medicine
נושאים:	Idiopathic pulmonary fibrosis Cost-effectiveness analysis Pirfenidone Nintedanib
גישה מקוונת:	https://doi.org/10.1186/s12890-021-01811-0
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!